CorVel Corp. $CRVL Shares Sold by UBS Group AG

UBS Group AG lessened its position in shares of CorVel Corp. (NASDAQ:CRVL) by 37.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 42,299 shares of the business services provider’s stock after selling 25,721 shares during the quarter. UBS Group AG owned approximately 0.08% of CorVel worth $2,862,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Principal Financial Group Inc. raised its stake in shares of CorVel by 15.6% during the 3rd quarter. Principal Financial Group Inc. now owns 162,111 shares of the business services provider’s stock worth $12,551,000 after buying an additional 21,827 shares during the last quarter. Argent Capital Management LLC acquired a new position in shares of CorVel during the 4th quarter worth $1,800,000. Thrivent Financial for Lutherans raised its stake in shares of CorVel by 14.6% during the 3rd quarter. Thrivent Financial for Lutherans now owns 458,326 shares of the business services provider’s stock worth $35,484,000 after buying an additional 58,323 shares during the last quarter. Y Intercept Hong Kong Ltd raised its stake in shares of CorVel by 665.2% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 26,383 shares of the business services provider’s stock worth $2,043,000 after buying an additional 22,935 shares during the last quarter. Finally, Algert Global LLC raised its stake in shares of CorVel by 73.4% during the 3rd quarter. Algert Global LLC now owns 217,559 shares of the business services provider’s stock worth $16,843,000 after buying an additional 92,077 shares during the last quarter. Institutional investors and hedge funds own 51.36% of the company’s stock.

Insiders Place Their Bets

In related news, insider Maxim Shishin sold 2,400 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $54.00, for a total value of $129,600.00. Following the completion of the transaction, the insider owned 7,050 shares of the company’s stock, valued at approximately $380,700. The trade was a 25.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 44.56% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded CorVel from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, April 6th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

CorVel Stock Performance

Shares of CRVL stock opened at $62.74 on Tuesday. The firm has a 50-day moving average price of $56.14 and a 200 day moving average price of $61.57. CorVel Corp. has a twelve month low of $44.83 and a twelve month high of $114.42. The company has a market capitalization of $3.21 billion, a price-to-earnings ratio of 29.32 and a beta of 0.98.

CorVel (NASDAQ:CRVL) last announced its earnings results on Tuesday, May 19th. The business services provider reported $0.61 earnings per share for the quarter. CorVel had a net margin of 11.51% and a return on equity of 29.92%. The firm had revenue of $248.55 million during the quarter.

CorVel Company Profile

CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.

The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).